entertainment -WSS

entertainment

author：comprehensive 2025-09-28 02:28:45 - browse：92395

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Why the drug industry's warnings on the IRA's impact fall short

WSS

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Senate bill would ban some hospital facility fees

Grad students accuse University of California of wage theft

FDA weighs limits of animal data in assessing artificial wombs

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

'A game

hotspot

entertainment

hotspot

How to save PrEP access — and even expand it

Why the drug industry's warnings on the IRA's impact fall short

Medicare proposal to cover medical devices draws a mixed reaction

Neurocrine congenital adrenal hyperplasia trial succeeds

DIEP, the 'gold standard' of breast reconstruction, is under threat

The unintended consequences of overturning Roe v. Wade

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Doctors in states that ban abortion can still help patients

Trump demands the U.S. pay no more for drugs than other countries … again

How the messy conversation about Dolly changed bioethics

hotspot

What AstraZeneca

Poland's lawmakers approve a divisive law on Russian influence

Doctors increasingly discourage vaping amid mounting health concerns

'Weather

Medicare to pay more for cardiac rehab in hospital outpatient clinics

5 wounded, 2 critically, in Michigan shopping center shooting

Wikipedia

leisure time

focus

leisure time